11 Result(s)
within
Klaus Oliver Schubert
-
Article
Open AccessExploring the genetics of lithium response in bipolar disorders
Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has bee...
-
Article
Open AccessAssociation of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consiste...
-
Article
Open AccessCorrection: Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients
-
Article
Open AccessCombining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients
Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs widely between individuals. The molecular mechanisms underlying treatment response heterogeneity are not well unders...
-
Article
Open AccessHLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders
Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and relia...
-
Article
Association of polygenic score for major depression with response to lithium in patients with bipolar disorder
Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap between depression and bip...
-
Article
The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression
Selective serotonin reuptake inhibitors (SSRIs) are first-line antidepressants for the treatment of major depressive disorder (MDD). However, treatment response during an initial therapeutic trial is often poo...
-
Article
Open AccessPharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry
Personalized medicine (personalized psychiatry in a specific setting) is a new model towards individualized care, in which knowledge from genomics and other omic pillars (microbiome, epigenomes, proteome, and ...
-
Chapter
Genetic Overlap Between Depression and Cardiometabolic Disorders
Depression and major cardiometabolic disorders (in this chapter, cardiometabolic disorders refer to the cardiovascular diseases, metabolic disorders, and associated risk factors) are highly heritable, i.e., th...
-
Article
Towards indicated prevention of psychosis: using probabilistic assessments of transition risk in psychosis prodrome
The concept of indicated prevention has proliferated in psychiatry, and accumulating evidence suggests that it may indeed be possible to prevent or delay the onset of a first episode of psychosis though adequa...
-
Article
Activation of STAT3 signaling in axotomized neurons and reactive astrocytes after fimbria–fornix transection
It is an open question to what extent neuroprotective mechanisms involving neurotrophic proteins are activated after central nervous system (CNS) lesions. Results from previous studies have indicated that cili...
